The Mosaic
Valve Clinical Performance at Seven Years: Results from a Multicenter
Prospective Clinical Trial |
|||||||
Background and aim of the study: The Mosaic valve
is a third-generation stented porcine bioprosthesis built upon the historical
durability of the Hancock II valve in an attempt to improve hemodynamic
performance and durability. |
Results: The mean gradient and calculated effective
orifice area average across all valve sizes remained stable at one, four
and six years. Freedom from valve-related adverse events (mean
± SE) at one, four and seven years after AVR were, respectively:
Anti-thromboembolic-related hemorrhage (ARH) 97.0 ± 0.6, 95.6 ±
0.9, and 94.6 ± 5.1%; primary hemolysis 100, 100, and 100%; and
structural valve deterioration (SVD) 100, 100 and 100%. Freedom at one,
four and seven years after MVR were: ARH 96.9 ± 1.2, 95.6 ± 2.0,
and 95.6
± 7.6%; primary hemolysis 100, 100, and 100%; and SVD 100, 100,
and 100%. Conclusion: These mid-term results demonstrate the clinical safety and excellent performance of the Mosaic valve. Continued follow up will determine if this new-design, third-generation bioprosthesis will provide increased durability. |
||||||
|
|||||||